I'm certain I wouldn't be alive without this medicine
For four decades, a mutated protein called KRAS drove pancreatic cancer's lethality while resisting every scientific attempt to stop it — earning the grim designation 'undruggable.' Now, a pill called daraxonrasib has done what generations of researchers could not: in a 501-patient international trial, it doubled median survival for metastatic pancreatic cancer patients, reducing mortality risk by 60 percent in a disease where fewer than one in thirty patients survives five years. The breakthrough, born from a 2013 discovery of a hidden flaw in KRAS's molecular surface, signals not merely a new treatment but a fundamental shift in what oncology believes possible.
- Pancreatic cancer kills 470,000 people annually and carries a stage-four survival rate of just 3%, making it one of medicine's most urgent and unresolved crises.
- For forty years, the KRAS protein — the engine of tumor growth in most pancreatic cancers — defeated every drug designed against it, leaving chemotherapy as the only blunt, limited option.
- A 501-patient international trial produced results without precedent: daraxonrasib extended median survival to 13.2 months versus 6.7 months on standard chemotherapy, a 60% reduction in mortality risk.
- The FDA has granted daraxonrasib breakthrough therapy status, with Revolution Medicines anticipating formal approval in 2025, potentially reaching thousands of patients within the year.
- The drug's promise is already expanding — trials targeting RAS-driven lung and colorectal cancers are underway, and a separate combination therapy also doubled survival in a parallel trial of 233 patients.
For more than forty years, the KRAS protein seemed to mock science. Mutated in the majority of pancreatic cancers, it locked tumor cells into a state of uncontrolled growth — and offered no surface where a drug could take hold. Researchers called it undruggable. Then in 2013, a UC San Francisco scientist named Kevan Shokat found a hidden crack in KRAS's structure. That crack became the foundation of everything that followed.
The drug that emerged from that discovery is called daraxonrasib. In an international trial of 501 patients with metastatic pancreatic cancer — a disease that kills most people within a year of diagnosis — those who received the drug lived a median of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The risk of death fell by 60 percent, a figure without precedent in the history of this cancer. Taken as a daily pill, daraxonrasib has already received FDA breakthrough therapy designation, with formal approval expected this year.
The road to the drug wound through decades of apparent failure. After Shokat's discovery, Harvard's Greg Verdine founded Warp Drive Bio and began engineering molecules that could force KRAS from its permanent cancerous 'on' state to 'off.' When Revolution Medicines acquired Warp Drive in 2018, the work accelerated into what became daraxonrasib. The trial that proved its worth enrolled patients from the United States, Europe, and Japan — all of whom had already undergone chemotherapy. The results were unambiguous: tumors shrank, disease markers fell, and side effects, while real, remained manageable.
For patients like Rhea Caras, a retired California lawyer diagnosed with metastatic pancreatic cancer in early 2023 and given months to live, the drug has meant something harder to measure than statistics. Two years into treatment, her tumor has significantly reduced. She plans trips with her family. 'I'm certain I wouldn't be alive without this medicine,' she said.
The implications reach beyond pancreatic cancer. Revolution Medicines is now testing daraxonrasib against lung and colorectal tumors, both of which carry high rates of RAS mutations. A separate combination therapy targeting a different tumor-growth protein also doubled survival in a parallel trial. Robert Weinberg, one of the scientists who first identified the RAS genes in 1982, has watched four decades of basic research finally arrive at the bedside. This is not a cure — but for thousands of patients who once faced only a countdown, it offers something nearly as rare: a future.
For more than forty years, scientists chased a ghost. The KRAS protein—a genetic regulator that, when mutated, turns cells cancerous—seemed to mock every attempt to stop it. It had no pocket, no crevice, nowhere for a drug molecule to grip and hold. Researchers called it undruggable. Then, in 2013, a scientist at UC San Francisco named Kevan Shokat found a crack in what he called the protein's greasy ball. That crack changed everything.
Today, a drug called daraxonrasib stands as proof that the impossible can become routine. In a trial of 501 patients with metastatic pancreatic cancer—the kind that has already spread, the kind that kills most people within a year—those who took daraxonrasib lived a median of 13.2 months. Those on standard chemotherapy lived 6.7 months. The drug doubled survival. It reduced the risk of death by 60 percent, a figure without precedent in the history of this disease.
Pancreatic cancer kills roughly 470,000 people each year worldwide. More than 500,000 are diagnosed annually. At stage four, the five-year survival rate hovers around 3 percent. Most patients learn they have the disease only when it is already advanced, when the tumor has metastasized, when time has become the scarcest resource. Until now, the standard response was chemotherapy—a blunt instrument that extended life by months, not years, and often at the cost of severe side effects. Daraxonrasib, taken as a pill once daily, changed the equation. The FDA has already granted it breakthrough therapy status, a designation that can accelerate approval. Revolution Medicines, the American biotech company that developed the drug, expects formal approval sometime this year.
The path to daraxonrasib wound through decades of apparent dead ends. After Shokat's 2013 discovery, the field began to shift. Greg Verdine at Harvard founded a company called Warp Drive Bio and applied a principle borrowed from nature: if molecular glues could bind different proteins together, perhaps an artificial molecule could inactivate KRAS. When Revolution Medicines acquired Warp Drive in 2018, the innovation accelerated. The company's chemists engineered a compound that could flip the mutated KRAS protein from its permanent "on" state—the cancerous state—to "off." That compound became daraxonrasib.
The international trial that proved its worth enrolled patients from the United States, Europe, and Japan, all of whom had already received chemotherapy. Half continued on the standard regimen. Half received daraxonrasib. The results were unambiguous. Patients on the new drug saw their tumors shrink significantly. Their tumor markers—objective measures of disease burden—fell. The side effects, while present, were manageable: rashes, mouth sores, diarrhea, nausea, fatigue. No new safety signals emerged. For a patient population that had been told to prepare for the end, the drug offered something previously unthinkable: time.
Rhea Caras, a retired lawyer from California, received her diagnosis of metastatic pancreatic cancer in early 2023. Her doctors gave her months. She enrolled in an intermediate trial of daraxonrasib. Two years later, she remains in treatment with significant tumor reduction. She plans trips with her family. "I'm certain I wouldn't be alive without this medicine," she said. She still contends with fatigue and nausea, but she now imagines living several more years—a prospect that seemed impossible before.
The breakthrough does not end with pancreatic cancer. Revolution Medicines is testing daraxonrasib in lung cancer and colorectal cancer, both of which carry high rates of RAS mutations and rank among the world's leading cancer killers. A parallel advance offers additional hope: a combination of chemotherapy and a drug called elraglusib, which blocks a different protein that fuels tumor growth, also doubled survival in a separate international trial of 233 patients, extending median survival to 10.1 months from 7.2 months. That combination is moving toward a phase three trial.
Robert Weinberg, one of the scientists who first identified the RAS genes in 1982, has watched four decades of basic research finally translate into clinical benefit. The scientific community agrees: this is not a cure, but it is a watershed. For the first time, a protein once thought completely beyond reach has been inhibited. For thousands of patients facing a diagnosis that has long meant a countdown, daraxonrasib offers something more precious than a cure: it offers a future.
Notable Quotes
I'm certain I wouldn't be alive without this medicine— Rhea Caras, retired lawyer with metastatic pancreatic cancer
Almost everyone thought it was going to be impossible to make drugs against KRAS— Marina Pasca di Magliano, University of Michigan researcher
The Hearth Conversation Another angle on the story
Why did it take forty years to find a way to stop this one protein?
Because KRAS has no obvious place for a drug to attach. Most proteins have pockets or grooves—think of a lock and key. KRAS is smooth. For decades, everyone assumed it was impossible.
What changed in 2013?
A scientist named Kevan Shokat found a small crack in the protein's surface. Not a pocket, exactly, but a flaw. That flaw meant the lock wasn't perfect. It meant a key could be designed.
And then what?
Other researchers realized that if you could find the crack, you could engineer a molecule to exploit it. Greg Verdine's team at Harvard thought about using molecular glues—substances that naturally bind proteins together. Revolution Medicines combined those ideas and built daraxonrasib.
The survival numbers are striking. Thirteen months versus seven.
Yes. For a disease where most people die within a year, six extra months is enormous. It's not a cure, but it's the first time we've actually extended life in a meaningful way for this population.
What about the side effects?
Rashes, mouth sores, diarrhea, nausea. Real, but manageable. The drug doesn't destroy healthy tissue the way chemotherapy does. That's the elegance of targeting KRAS specifically—you're hitting the cancer without poisoning the patient.
Will it work in other cancers?
That's the next frontier. Lung cancer and colorectal cancer both have high rates of RAS mutations. If daraxonrasib works there too, the impact could be enormous. We're talking about some of the deadliest cancers on Earth.